We are live on ! Find out more
SC

Sophrosyne Capital Portfolio holdings

AUM $11.5M
1-Year Est. Return 17.82%
This Fund
S&P 500
This Quarter Est. Return
+16.88%
1 Year Est. Return
+17.82%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$64.8M
AUM Growth
-$19.9M
Cap. Flow
-$24.5M
Cap. Flow %
-37.79%
Top 10 Hldgs %
64.49%
Holding
63
New
5
Increased
6
Reduced
22
Closed
23

Top Buys

Rank Stock Value
1
CYNO
Cynosure, Inc. Class A
CYNO
+$576K
2
IPHI
INPHI CORPORATION
IPHI
+$541K
3
RTK
Rentech, Inc.
RTK
+$444K
4
CEMI
Chembio diagnostics, Inc.
CEMI
+$428K
5
REFR icon
Research Frontiers
REFR
+$413K

Top Sells

Rank Stock Value
1
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$5M
2
MSTR icon
Strategy Inc
MSTR
+$2.79M
3
ARCT icon
Arcturus Therapeutics
ARCT
+$2.47M
4
FLNA
Filana Therapeutics
FLNA
+$2.27M
5
DRRX
DURECT Corp
DRRX
+$1.77M

Sector Composition

Rank Sector Weight
1 Healthcare 50%
2 Technology 18.71%
3 Utilities 9.18%
4 Communication Services 7.12%
5 Financials 5.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCPC
26
Balchem Corp
BCPC
$5.67B
$654K 1.01%
9,800
– –
CLRB icon
27
Cellectar Biosciences
CLRB
$24M
$441K 0.68%
5
-1
-17% -$77K
REFR icon
28
Research Frontiers
REFR
$16.9M
$418K 0.64%
+81,629
New +$413K
CEMI
29
DELISTED
Chembio diagnostics, Inc.
CEMI
$407K 0.63%
+103,400
New +$428K
CYNI
30
DELISTED
CYAN INC COM
CYNI
$254K 0.39%
101,773
-118,926
-54% -$325K
SMSI icon
31
Smith Micro Software
SMSI
$16.5M
$159K 0.25%
1,026
-242
-19% -$35.6K
MCUR
32
DELISTED
Macrocure Ltd.
MCUR
$146K 0.23%
20,000
– –
RNF
33
DELISTED
RENTECH NITROGEN PARTNERS, L.P. INT
RNF
$133K 0.21%
+12,700
New +$139K
GENC icon
34
Gencor Industries
GENC
$280M
$114K 0.18%
+18,225
New +$118K
SLB icon
35
SLB Ltd
SLB
$81.6B
$102K 0.16%
1,200
– –
RVLT
36
DELISTED
Revolution Lighting Technologies, Inc. - Class A
RVLT
$102K 0.16%
+7,528
New +$115K
LNG icon
37
Cheniere Energy
LNG
$58B
$99K 0.15%
1,400
– –
GLOG
38
DELISTED
GASLOG LTD
GLOG
$41K 0.06%
2,000
– –
GTLS
39
DELISTED
Chart Industries
GTLS
$30K 0.05%
875
– –
ARCT icon
40
Arcturus Therapeutics
ARCT
$460M
– –
-22,832
Closed -$2.47M
CP icon
41
Canadian Pacific Kansas City
CP
$82.5B
– –
-2,875
Closed -$119K
CVGW
42
DELISTED
Calavo Growers
CVGW
– –
-1,600
Closed -$72K
DRRX
43
DELISTED
DURECT Corp
DRRX
– –
-120,211
Closed -$1.77M
KTOS icon
44
Kratos Defense & Security Solutions
KTOS
$10.1B
– –
-15,000
Closed -$98K
LMNR icon
45
Limoneira
LMNR
$246M
– –
-4,400
Closed -$104K
LPSN icon
46
LivePerson
LPSN
$34.4M
– –
-7,700
Closed -$1.45M
MITK icon
47
Mitek Systems
MITK
$867M
– –
-20,000
Closed -$48K
SANW
48
DELISTED
S&W Seed Co
SANW
– –
-13,892
Closed -$1.12M
FLNA
49
Filana Therapeutics
FLNA
$44.6M
– –
-83,109
Closed -$2.27M
SQNS
50
Sequans Communications SA
SQNS
$44.3M
– –
-2,250
Closed -$444K
1
2
3

Similar funds

SFM
Socratic Fund Management Short Hills, New Jersey $12M AUM 39.3% 1-Year Est. Return
IACGFA
IDG-Accel China Growth Fund Associates Central, Hong Kong $13.2M AUM 31.6% 1-Year Est. Return
LS
Lupo Securities Chicago, Illinois $13.3M AUM 1.59% 1-Year Est. Return
NGPI
N.G. Partners II Palo Alto, California $9.65M AUM 70.44% 1-Year Est. Return
AP
AGTC Partners Cambridge, Massachusetts $13.6M AUM 15.62% 1-Year Est. Return
GRP
Geologic Resource Partners Boston, Massachusetts $9.22M AUM 48.14% 1-Year Est. Return
NVPV
Norwest Venture Partners VIII Palo Alto, California $9.22M AUM
AC
Amiya Capital London, United Kingdom $14.3M AUM 4.61% 1-Year Est. Return

Sophrosyne Capital's Q4 2014 Portfolio in Review

As of Q4 2014, Sophrosyne Capital held 63 positions worth $64.8M, down 23% from $84.7M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Sophrosyne Capital withdrew a net $24.5M in Q4 2014, closing 23 positions and reducing 22 holdings. Its most notable exit was Arcturus Therapeutics, an estimated $2.47M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 44% a quarter earlier, followed by Technology and Utilities.

Against the trend, Sophrosyne Capital opened a new position in Chembio diagnostics, Inc. worth $407K.

  • Sophrosyne Capital's largest Q4 2014 buy was Chembio diagnostics, Inc.: 103,400 shares worth $407K.
  • Sophrosyne Capital added most to Cynosure, Inc. Class A in Q4 2014, an estimated $576K increase.
  • Sophrosyne Capital's biggest Q4 2014 reduction was ZELTIQ Aesthetics, Inc., cutting an estimated $5M.
  • Sophrosyne Capital fully exited Arcturus Therapeutics in Q4 2014, selling an estimated $2.47M.
  • Sophrosyne Capital's ten largest holdings make up 64% of its $64.8M portfolio in Q4 2014.
  • Sophrosyne Capital opened 5 new positions and closed 23 in Q4 2014.
  • Sophrosyne Capital's portfolio value fell 23% quarter-over-quarter to $64.8M.

Based on Sophrosyne Capital's 13F filing for Q4 2014, filed 26 Jan 2015.